Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 532

1.

The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease.

Bossuyt P, Debeuckelaere C, Ferrante M, Vanbeckevoort D, Billiet T, Wolthuis A, van Assche G, D'Hoore A, Vermeire S.

Eur J Gastroenterol Hepatol. 2018 Feb 16. doi: 10.1097/MEG.0000000000001091. [Epub ahead of print]

PMID:
29462028
2.

Long-Term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease.

Hoekman DR, Stibbe JA, Baert FJ, Caenepeel P, Vergauwe P, De Vos M, Hommes DW, Benninga MA, Vermeire SA, D'Haens GR; BIRD (Belgian Inflammatory Bowel Disease Research and Development) Group; North-Holland Gut Club.

J Crohns Colitis. 2018 Feb 1. doi: 10.1093/ecco-jcc/jjy014. [Epub ahead of print]

PMID:
29401297
3.

Immunogenicity of biologics in inflammatory bowel disease.

Vermeire S, Gils A, Accossato P, Lula S, Marren A.

Therap Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355. doi: 10.1177/1756283X17750355. eCollection 2018.

4.

Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.

Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2018 Mar;47(6):773-783. doi: 10.1111/apt.14514. Epub 2018 Jan 19.

PMID:
29349829
5.

Autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's Disease: a review on behalf of ECCO and EBMT.

Snowden JA, Panés J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P, Hawkey C, Kazmi M, Lindsay JO, Onida F, Salas A, Saccardi R, Vermeire S, Rovira M, Ricart E; European Crohn’s and Colitis Organisation (ECCO), European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT.

J Crohns Colitis. 2018 Jan 8. doi: 10.1093/ecco-jcc/jjx184. [Epub ahead of print]

PMID:
29325112
6.

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.

D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D; GETAID.

Gastroenterology. 2018 Jan 6. pii: S0016-5085(18)30015-5. doi: 10.1053/j.gastro.2018.01.004. [Epub ahead of print]

PMID:
29317275
7.

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).

Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S.

Gut. 2017 Dec 15. pii: gutjnl-2017-314562. doi: 10.1136/gutjnl-2017-314562. [Epub ahead of print]

8.

Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiology.

Noben M, Vanhove W, Arnauts K, Santo Ramalho A, Van Assche G, Vermeire S, Verfaillie C, Ferrante M.

United European Gastroenterol J. 2017 Dec;5(8):1073-1081. doi: 10.1177/2050640617722903. Epub 2017 Jul 21. Review.

9.

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.

Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A.

Aliment Pharmacol Ther. 2018 Feb;47(3):346-355. doi: 10.1111/apt.14452. Epub 2017 Dec 11.

PMID:
29226370
10.

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease - an International, Cross-disciplinary Consensus.

Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, Derieppe M, Dignass A, Driscoll R, Fitzpatrick R, Gaarentstroom-Lunt J, Higgins PD, Kotze PG, Meissner J, O'Connor M, Ran ZH, Siegel CA, Terry H, van Deen WK, van der Woude CJ, Weaver A, Yang SK, Sands BE, Vermeire S, Travis SP.

J Crohns Colitis. 2017 Dec 5. doi: 10.1093/ecco-jcc/jjx161. [Epub ahead of print]

PMID:
29216349
11.

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab.

Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S.

Clin Gastroenterol Hepatol. 2017 Dec 1. pii: S1542-3565(17)31419-2. doi: 10.1016/j.cgh.2017.11.046. [Epub ahead of print]

PMID:
29203225
12.

Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.

van Hoeve K, Hoffman I, Vermeire S.

Expert Opin Drug Saf. 2018 Feb;17(2):185-196. doi: 10.1080/14740338.2018.1413090. Epub 2017 Dec 10. Review.

PMID:
29202588
13.

Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.

Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ.

Aliment Pharmacol Ther. 2018 Jan;47(2):229-237. doi: 10.1111/apt.14421. Epub 2017 Nov 21.

14.

Quantitative microbiome profiling links gut community variation to microbial load.

Vandeputte D, Kathagen G, D'hoe K, Vieira-Silva S, Valles-Colomer M, Sabino J, Wang J, Tito RY, De Commer L, Darzi Y, Vermeire S, Falony G, Raes J.

Nature. 2017 Nov 23;551(7681):507-511. doi: 10.1038/nature24460. Epub 2017 Nov 15.

PMID:
29143816
15.

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time.

Bian S, Dreesen E, Tang HT, Compernolle G, Peeters M, Van Assche G, Ferrante M, Vermeire S, Gils A.

Inflamm Bowel Dis. 2017 Dec;23(12):2202-2208. doi: 10.1097/MIB.0000000000001255.

PMID:
29140943
16.

NOD2 and bacterial recognition as therapeutic targets for Crohn's disease.

de Bruyn M, Vermeire S.

Expert Opin Ther Targets. 2017 Dec;21(12):1123-1139. doi: 10.1080/14728222.2017.1397627. Epub 2017 Nov 2. Review.

PMID:
29096557
17.

Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study.

Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, Danese S, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A, Sandborn WJ, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N.

Clin Transl Gastroenterol. 2017 Nov 2;8(11):e126. doi: 10.1038/ctg.2017.52.

18.

Outcome of restorative proctocolectomy with an ileo-anal pouch for ulcerative colitis: effect of changes in clinical practice.

Germain A, de Buck van Overstraeten A, Wolthuis A, Ferrante M, Vermeire S, Van Assche G, D'Hoore A.

Colorectal Dis. 2018 Feb;20(2):O30-O38. doi: 10.1111/codi.13948.

PMID:
29091335
19.

Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC.

Conceição-Neto N, Deboutte W, Dierckx T, Machiels K, Wang J, Yinda KC, Maes P, Van Ranst M, Joossens M, Raes J, Vermeire S, Matthijnssens J.

Gut. 2017 Oct 24. pii: gutjnl-2017-315281. doi: 10.1136/gutjnl-2017-315281. [Epub ahead of print] No abstract available.

20.

Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease.

Vanhove W, Nys K, Arijs I, Cleynen I, Noben M, De Schepper S, Van Assche G, Ferrante M, Vermeire S.

J Crohns Colitis. 2018 Jan 24;12(2):178-187. doi: 10.1093/ecco-jcc/jjx122.

PMID:
29029005
21.

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A, Bayliss M, Maher S, Cappelleri JC, Bushmakin AG, Rubin DT.

J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133.

PMID:
29028981
22.

Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy.

Ferrante M, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D'Hoore A.

J Crohns Colitis. 2017 Oct 27;11(11):1353-1361. doi: 10.1093/ecco-jcc/jjx095.

PMID:
28981886
23.

Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model.

Bossuyt P, Debeuckelaere C, Ferrante M, de Buck van Overstraeten A, Vanbeckevoort D, Billiet T, Wolthuis A, Cleynen I, Van Assche G, D'Hoore A, Vermeire S.

J Crohns Colitis. 2018 Jan 5;12(1):32-38. doi: 10.1093/ecco-jcc/jjx110.

PMID:
28981768
24.

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.

D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O.

J Crohns Colitis. 2018 Jan 24;12(2):188-196. doi: 10.1093/ecco-jcc/jjx128.

PMID:
28961770
25.

Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease.

Vancamelbeke M, Vanuytsel T, Farré R, Verstockt S, Ferrante M, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijs I, Cleynen I.

Inflamm Bowel Dis. 2017 Oct;23(10):1718-1729. doi: 10.1097/MIB.0000000000001246.

PMID:
28885228
26.

Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.

Boland BS, Vermeire S.

Gastroenterol Clin North Am. 2017 Sep;46(3):627-644. doi: 10.1016/j.gtc.2017.05.015. Review.

PMID:
28838419
27.

PR3-anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis.

Mahler M, Damoiseaux J, Ballet V, Dillaerts D, Bentow C, Cohen Tervaert JW, Blockmans D, Boeckxstaens G, Aguilera-Lizarraga J, Csernok E, Vermeire S, Bossuyt X.

Clin Chem Lab Med. 2017 Nov 27;56(1):e27-e30. doi: 10.1515/cclm-2017-0346. No abstract available.

PMID:
28755529
28.

Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres.

de Buck van Overstraeten A, Eshuis EJ, Vermeire S, Van Assche G, Ferrante M, D'Haens GR, Ponsioen CY, Belmans A, Buskens CJ, Wolthuis AM, Bemelman WA, D'Hoore A.

Br J Surg. 2017 Nov;104(12):1713-1722. doi: 10.1002/bjs.10595. Epub 2017 Jul 26.

PMID:
28745410
29.

Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's disease.

Bian S, Lu J, Delport F, Vermeire S, Spasic D, Lammertyn J, Gils A.

Drug Test Anal. 2017 Jul 25. doi: 10.1002/dta.2250. [Epub ahead of print]

PMID:
28743169
30.

Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial.

Bisschops R, Bessissow T, Joseph JA, Baert F, Ferrante M, Ballet V, Willekens H, Demedts I, Geboes K, De Hertogh G, Vermeire S, Rutgeerts P, Van Assche G.

Gut. 2017 Jul 11. pii: gutjnl-2016-313213. doi: 10.1136/gutjnl-2016-313213. [Epub ahead of print]

PMID:
28698230
31.

Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO).

Wauters L, Smets F, De Greef E, Bontems P, Hoffman I, Hauser B, Alliet P, Arts W, Peeters H, Van Biervliet S, Paquot I, Van de Vijver E, De Vos M, Bossuyt P, Rahier JF, Dewit O, Moreels T, Franchimont D, Muls V, Fontaine F, Louis E, Coche JC, Baert F, Paul J, Vermeire S, Veereman G.

Inflamm Bowel Dis. 2017 Sep;23(9):1584-1591. doi: 10.1097/MIB.0000000000001193.

PMID:
28696956
32.

Fine-mapping inflammatory bowel disease loci to single-variant resolution.

Huang H, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson CA, Andersen V, Cleynen I, Cortes A, Crins F, D'Amato M, Deffontaine V, Dmitrieva J, Docampo E, Elansary M, Farh KK, Franke A, Gori AS, Goyette P, Halfvarson J, Haritunians T, Knight J, Lawrance IC, Lees CW, Louis E, Mariman R, Meuwissen T, Mni M, Momozawa Y, Parkes M, Spain SL, Théâtre E, Trynka G, Satsangi J, van Sommeren S, Vermeire S, Xavier RJ; International Inflammatory Bowel Disease Genetics Consortium, Weersma RK, Duerr RH, Mathew CG, Rioux JD, McGovern DPB, Cho JH, Georges M, Daly MJ, Barrett JC.

Nature. 2017 Jul 13;547(7662):173-178. doi: 10.1038/nature22969. Epub 2017 Jun 28.

33.

The intestinal barrier: a fundamental role in health and disease.

Vancamelbeke M, Vermeire S.

Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):821-834. doi: 10.1080/17474124.2017.1343143. Epub 2017 Jun 26.

PMID:
28650209
34.

Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.

Billiet T, Cleynen I, Ballet V, Claes K, Princen F, Singh S, Ferrante M, Van Assche G, Gils A, Vermeire S.

Scand J Gastroenterol. 2017 Oct;52(10):1086-1092. doi: 10.1080/00365521.2017.1339825. Epub 2017 Jun 16.

PMID:
28622097
35.

Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study.

Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T, Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Har-Noy O, Bossuyt P, Mantzaris G, Barreiro de Acosta M, Chaparro M, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, Ferrante M, Sonnenberg E, Siegmund B, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vermeire S, Ben-Horin S, Roblin X.

Inflamm Bowel Dis. 2017 Sep;23(9):1605-1613. doi: 10.1097/MIB.0000000000001160.

PMID:
28590343
36.

A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.

Verstockt B, Deleenheer B, Van Assche G, Vermeire S, Ferrante M.

Expert Opin Drug Saf. 2017 Jul;16(7):809-821. doi: 10.1080/14740338.2017.1338273. Epub 2017 Jun 9. Review.

PMID:
28573876
37.

Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease.

de Bruyn M, Breynaert C, Arijs I, De Hertogh G, Geboes K, Thijs G, Matteoli G, Hu J, Van Damme J, Arnold B, Ferrante M, Vermeire S, Van Assche G, Opdenakker G.

Nat Commun. 2017 May 31;8:15384. doi: 10.1038/ncomms15384.

38.

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W.

Lancet. 2017 Jul 8;390(10090):135-144. doi: 10.1016/S0140-6736(17)30930-3. Epub 2017 May 17.

PMID:
28527704
39.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators.

N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.

40.

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.

Van Stappen T, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A.

Gut. 2017 Apr 27. pii: gutjnl-2016-313071. doi: 10.1136/gutjnl-2016-313071. [Epub ahead of print]

PMID:
28450388
41.

Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.

Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M.

Aliment Pharmacol Ther. 2017 May;45(9):1284. doi: 10.1111/apt.14054. No abstract available.

PMID:
28370036
42.

Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.

Noman M, Ferrante M, Bisschops R, De Hertogh G, Van den Broeck K, Rans K, Rutgeerts P, Vermeire S, Van Assche G.

J Crohns Colitis. 2017 Sep 1;11(9):1085-1089. doi: 10.1093/ecco-jcc/jjx048.

PMID:
28369329
43.

Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor.

Lu J, Spasic D, Delport F, Van Stappen T, Detrez I, Daems D, Vermeire S, Gils A, Lammertyn J.

Anal Chem. 2017 Mar 21;89(6):3664-3671. doi: 10.1021/acs.analchem.6b05092. Epub 2017 Mar 3.

PMID:
28222600
44.

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.

Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E.

Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16.

45.

A microbial signature for Crohn's disease.

Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, Martinez X, Varela E, Sarrabayrouse G, Machiels K, Vermeire S, Sokol H, Guarner F, Manichanh C.

Gut. 2017 May;66(5):813-822. doi: 10.1136/gutjnl-2016-313235. Epub 2017 Feb 7.

46.

Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.

Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M.

Aliment Pharmacol Ther. 2017 Apr;45(7):941-950. doi: 10.1111/apt.13960. Epub 2017 Feb 7.

PMID:
28169436
47.

Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.

Van Steenbergen S, Bian S, Vermeire S, Van Assche G, Gils A, Ferrante M.

Aliment Pharmacol Ther. 2017 Apr;45(7):923-932. doi: 10.1111/apt.13964. Epub 2017 Feb 6.

PMID:
28164321
48.

Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?

Noben M, Verstockt B, de Bruyn M, Hendriks N, Van Assche G, Vermeire S, Verfaillie C, Ferrante M.

Gut. 2017 Dec;66(12):2193-2195. doi: 10.1136/gutjnl-2016-313667. Epub 2017 Feb 3. No abstract available.

PMID:
28159838
49.

Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care.

Coenen S, Weyts E, Vermeire S, Ferrante M, Noman M, Ballet V, Vanhaecht K, Van Assche G.

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):646-650. doi: 10.1097/MEG.0000000000000839.

PMID:
28118176
50.

Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease.

Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, Vermeire S, Van Assche G, Ferrante M.

Inflamm Bowel Dis. 2017 Feb;23(2):318-324. doi: 10.1097/MIB.0000000000001013.

PMID:
28079621

Supplemental Content

Loading ...
Support Center